Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Conditions
Interventions
LY3022855
Vemurafenib
+1 more
Locations
1
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
June 6, 2017
Primary Completion Date
October 21, 2020
Completion Date
November 11, 2020
Last Updated
July 17, 2024
NCT07177937
NCT02621021
NCT03050268
NCT03340506
NCT05969860
NCT04693377
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions